

Testing process

Rhythm Biosciences works with 4Cyte Pathology to collect and send patient samples to our NATA-accredited facility.

A list of collection facilities is available at colostat.com or scan the QR code here.

We return patient results to you, allowing you to act quickly on them.



About Rhythm Biosciences and ColoSTAT®

Rhythm Biosciences is an Australian diagnostics company focused on developing simple, affordable and accurate tests for the early detection of cancers.

Rhythm Biosciences developed ColoSTAT® from innovative CSIRO research.

The technology simplifies the testing process for Colorectal Cancer (CRC) and may help to speed up diagnosis and reduce morbidity and mortality rates.

ColoSTAT® has been clinically validated across multiple populations, with data supporting its ability to detect early-stage CRC with high accuracy.

References

1. Internal data, Rhythm Biosciences 2025
2. AIHW, National Bowel Cancer Screening Program monitoring report 2025

AU-HCP-COLOSTAT-1-3

Triage potential colorectal cancer patients quickly and effectively with ColoSTAT®



COLOSTAT®
Colorectal Cancer Test

RHYTHM
BIOSCIENCES

COLOSTAT®
Colorectal Cancer Test

Find out more about how ColoSTAT® can support you to quickly, safely and effectively triage patients with symptoms of CRC by emailing support@rhythmbio.com or visiting www.rhythmbio.com.

ColoSTAT® is a clinically validated blood test that supports colorectal cancer (CRC) diagnosis in symptomatic patients.


Developed by Rhythm Biosciences, from CSIRO research, ColoSTAT® allows you to triage smarter, act early, reduce unnecessary referrals and offer an alternative to a Faecal Immunochemical Test (FIT).

Patients presenting with vague abdominal symptoms are common. ColoSTAT® checks for protein markers that indicate the likely presence of CRC and may complement other blood tests, such as those for IBS, Crohn's or inflammatory bowel disease, to rule out the presence of CRC.

Benefits of ColoSTAT®

- ✓ Blood, rather than stool-based
- ✓ Clinically safe for patients with symptoms of CRC
- ✓ 90% sensitivity, comparable to stool-based FIT tests, directly detecting biomarkers of cancer¹
- ✓ NPV of 99.4% means you can be confident when a patient receives a negative result they do not have the disease¹
- ✓ Supports risk-stratification in difficult to characterise cases e.g. persistent symptoms in frail or FIT-reluctant patients
- ✓ Minimises unnecessary referrals, reducing the chance of missing cancers
- ✓ Improves patient compliance by offering a simple, acceptable option right at your clinic
- ✓ Reduces the burden on the healthcare system as colonoscopy wait times exceed recommended targets

ColoSTAT® performance¹



ColoSTAT® Sensitivity (%) at each Cancer Stage				
I	II	III	IV	Advanced Adenomas
85.0%	95.7%	84.4%	100.0%	58.0%

Internal data, Rhythm Biosciences 2025

Intended use claim

ColoSTAT® is a quantitative multiplex immunoassay that detects protein biomarkers in human serum. It is intended for people with symptoms of colorectal cancer.

A positive result may indicate the presence of colorectal neoplasia and should be followed up with a colonoscopy.

ColoSTAT® is not a replacement for diagnostic colonoscopy, or for surveillance colonoscopy in high-risk individuals.

Perfect for low risk patients

- ✓ aged 45-84
- ✓ with symptoms of bowel cancer
- ✓ reluctant to do stool-based tests

